1. H. Ulukan, and P. W. Swaan. Camptothecins: a review of their chemotherapeutic potential. Drugs. 62:2039–2057 (2002).
2. Y. Shimada, M. Rothenberg, S. G. Hilsenbeck, H. A. Burris III, D. Degen, and D. D. Von Hoff. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 5:202–206 (1994).
3. P. J. Houghton, P. J. Cheshire, J. C. Hallman, M. C. Bissery, A. Mathieu-Boue, and J. A. Houghton. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res. 53:2823–2829 (1993).
4. P. Calabresi, B. A. Chabner, J. G. Hardman, and L. E. Limbird. Chemotherapy of Neoplastic Diseases, Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 10McGraw-Hill (Medical Publishing Division), New York, 2001, p. 1424.
5. H. Ulukan, M. T. Muller, and P. W. Swaan. Downregulation of topoisomerase I in differentiating human intestinal epithelial cells. Int. J. Cancer. 94:200–207 (2001).